

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF FIRST INTERIM ANALYSIS OF PHASE III CLINICAL
TRIAL OF TANFANERCEPT (HBM9036)

This announcement is made by HBM Holdings Limited (the “**Company**” or “**Harbour BioMed**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, the Company has completed its first interim analysis of phase III clinical trial in China of tanfanercept (HBM9036), a new global innovative tumor necrosis factor (TNF) receptor-1 fragment-based drug for adult patients with moderate-to-severe dry eye disease (DED). The trial was planned to enroll 674 patients and to conduct two interim analyses over the course of the trial.

As of 28 December 2021, a total number of 187 patients have been evaluated for key efficacy endpoints assessment. The first interim analysis was performed according to trial protocol, and the interim data were reviewed by the Independent Data Monitoring Committee (the “**IDMC**”). As a result of its observed efficacy trend and favorable safety, the study was recommended by the IDMC to be continued according to the current protocol. As of the date of this announcement, the Company remains blinded to whether the participants involved in the trial received drug or placebo. Further announcement(s) regarding the details and developments of the phase III clinical trial will be made by the Company as and when appropriate.

About Tanfanercept (HBM9036)

Tanfanercept (HBM9036) is a modified 19 kDa TNF receptor-1 fragment originally developed by HanAll Biopharma as an ophthalmic solution with good eye permeability, strong TNF- α neutralizing activity, high stability, and minor side effects. Based on a licensing agreement, Harbour BioMed owns the exclusive rights for development and commercialization of tanfanercept in mainland China, Taiwan, Hong Kong, and Macao.

About Dry Eye Disease (DED)

DED is a chronic, multifactorial ocular disease that can cause visual disturbance and long-term damage of the ocular surface, with a significant impact on quality of life. It currently affects 21-30% patients in China. The prevalence of this ocular disease is expected to grow significantly, fueled by a growing aging population worldwide, excessive use of smartphones, and environmental changes. Artificial tears, which only provide temporary symptomatic relief, are still the most used treatment for DED in China, representing a large unmet need in the Chinese market.

Cautionary Statement: we cannot guarantee that we will be able to develop, or ultimately market, tanfanercept (HBM9036) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 13 January 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Mr. Xiaoxiang Chen as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.